bjgabrielsen

Sanibel, Florida; BJ Gabrielsen photo

Bone Scans for Metastatic Prostate Cancer

The most troubling thought for prostate cancer patients whose cancer has recurred after an initial radicalprostatectomy is the fact that there are PSA-producing cells located somewhere in our bodies. While subsequent treatments such as androgen deprivation (hormonal) therapy may keep these cells under control, there are undoubtedly micro-metastases somewhere in our bodies. When the controlling more »

NewsPulse, a Medical Resource from the Prostate Cancer Foundation. Biomarkers in Urine for the Detection of Prostate Cancer.

Sources of current medical information concerning prostate cancer are listed on this website under the section Medical Resources.  Recently, a new August 2011 electronic newsletter entitled NewsPulse was received from the Prostate Cancer Foundation. The issue contained very current information on specific diagnostic methods, biomarkers for cancer detection, targeted therapies and drugs under development, nutrition and more »

Information from Johns Hopkins: a) Use of Immunotherapies (Provenge, Prostvac) Against Prostate Cancer; and, b) Gleason Scores.

Provenge (sipuleucel-T) was the first approved prostate cancer therapy which uses a person’s immune system to fight the disease.  Its approval was limited to men with advanced prostate cancer who have not responded to other treatments like hormonal (androgen deprivation) therapy and are experiencing few or no symptoms. Cost and supply remain significant issues hindering more »

Good News!

My prostate-specific antigen (PSA) level was again below detectable limits, 0.01 ng/mL. The prostate cancer is still under control! God’s plan, presence, protection, power and promises again prevailed over my apprehension and fears. Christ’s perfect love truly never fails! The scene above overlooking Charlotte Harbor as it leads to the Gulf of Mexico is from a scenic more »

GOOD NEWS!!! New Regimens and Therapeutic Agents in the Pipeline; a Visit with my Oncologist.

Every six months, I have an appointment with my oncologist at the Moffitt Cancer Center, on the campus of the University of South Florida, in Tampa. Moffitt is a designated National Cancer Institute (NCI, National Institutes of Health, my former employer) Comprehensive Cancer Center, a highly-sought-after distinction. My oncologist had been highly recommended to me more »

Countering Weight Gain as a Result of Hormonal Therapy.

Benefits and risks accompany virtually every method of treatment. Hormonal therapy for prostate cancer is no exception. Potential risks include osteoporosis and bone fractures, cardiac effects, diabetes, depression, hot flashes and metabolic changes resulting in weight gain. (These issues are discussed on this website under “My Story”, 2009 entries of July 5th-27th, September 29th, October more »

FDA Approves Abiraterone (Zytiga) for Advanced Prostate Cancer

(An initial blog was published on this website on Jan. 8th, 2011, describing results from late stage clinical trials of abiraterone acetate in hormone-refractory prostate cancer patients.) On April 28th, the Food and Drug Administration (FDA) approved abiraterone (Zytiga) for the treatment of men with metastatic castration (hormone)-resistant prostate cancer (meaning the disease progresses despite more »

Peace when most needed.

Monday, March 7th, 2011 was my day for my 4-month PSA test in preparation for my urologist appointment next week. In the past, the week leading up to the PSA test had been characterized by periods of mild depression and apprehension. But the intensity and frequency of these episodes had been on the decrease. In more »

Avodart (dutasteride) used to treat benign prostatic hyperplasia (BPH) may slow the growth of early-stage prostate cancer

A recent study presented on Feb. 17-19th  at the 2011 Genitourinary Cancers Symposium in Orlando, FL by researchers from the University Health Network in Toronto, Canada concluded that for men who are undergoing “watchful-waiting” for prostate cancer, Avodart could help control the disease and prevent the need for more aggressive treatments. “Watchful waiting,” or active-surveillance more »

Promising results for the late-stage prostate cancer drug, MDV3100.

MDV 3100 is a promising new treatment under clinical development by Medivation, Inc. and Astellas Pharma Inc. for advanced prostate cancer patients who have already received chemotherapy with taxotere (docetaxel) as well as those who have not been treated with taxotere.  MDV3100 slows growth and induces cell death in bicalutamide (casodex)-resistant cancers via three complementary more »

Are you contemplating open versus minimally-invasive prostate cancer surgery?

The Johns Hopkins Hospital in Baltimore, Maryland is recognized as possessing the foremost urology department in America according to the annual hospital survey in U.S. News and World Reports.  A recent article by Dr. Alan Partin from Johns Hopkins and published on January 26th, 2011 in the Johns Hopkins Health Alerts described the various surgical options for prostate cancer more »

Colon cancer-a side effect of hormonal therapy.

A recent study published in the November 10th issue of the Journal of the National Cancer Institute reported that prostate cancer hormone treatments may raise the risk of colorectal cancer.  Lowering the male sex hormones by treatment with gonadotropin-releasing hormone (GnRH) agonists (hormonal therapy) or surgical removal of the testicles to lower testosterone and PSA levels led more »